Georgia's Online Cancer Information Center


back

Lung Cancer Clinical Trials in Georgia

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Cancer Type = Lung Cancer
Cancer Type = Lung Cancer
NCI ID Cancer Type Trial Name
There are currently 72 active Lung Cancer clinical trials in Georgia.
NCI ID Cancer Type Trial Name
1.
A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection
Cancer Type
Lung Cancer
NCT ID
NCT05120349
Protocol IDs
D516FC00001
NCI-2022-03173
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
2.
A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer
Cancer Type
Lung Cancer
NCT ID
NCT01630733
Protocol IDs
TV1011-LC-303
2012-002447-14
3.
A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies
Cancer Type
Gynecologic Cancers, Lung Cancer, Primary Peritoneal Cancer
NCT ID
NCT05199272
Protocol IDs
23ME-00610-CLIN-001
NCI-2022-03572
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
4.
A Prospective Observational Study to Estimate the Incidence of Febrile Neutropenia (FN) Among Subjects With Non-myeloid Malignancies at High Risk for FN and Receiving Neulasta® (pegfilgrastim) Onpro® kit or Other Physician Choice Options for Prophylaxis of Febrile Neutropenia
Cancer Type
Breast Cancer, Lung Cancer, Non-Hodgkin Lymphoma, Prostate Cancer
NCT ID
Protocol IDs
AMG 011 20170758
5.
A Prospective Observational Study to Estimate the Incidence of Febrile Neutropenia (FN) Among Subjects With Non-myeloid Malignancies at High Risk for FN and Receiving Neulasta® (pegfilgrastim) Onpro® kit or Other Physician Choice Options for Prophylaxis of FN
Cancer Type
Breast Cancer, Lung Cancer, Non-Hodgkin Lymphoma, Prostate Cancer
NCT ID
Protocol IDs
AMG 011 20170758
6.
A Registry of Cesium-131 Brachytherapy Plus Sub- lobar Resection for Early Stage Lung Cancer
Cancer Type
Lung Cancer
NCT ID
Protocol IDs
7.
A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer
Cancer Type
Lung Cancer
NCT ID
NCT04620330
Protocol IDs
VS-6766-202
NCI-2021-01997
8.
A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors
Cancer Type
Colon/Rectal Cancer, Liver Cancer / Hepatoblastoma, Lung Cancer
NCT ID
NCT04943900
Protocol IDs
CA102-003
NCI-2021-09090
9.
A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors
Cancer Type
Brain & Spinal Cord Tumor, Lung Cancer, Sarcoma
NCT ID
NCT05538572
Protocol IDs
PRT3645-01
NCI-2022-09871
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
10.
A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer
Cancer Type
Lung Cancer, Lymphoma, Neuroendocrine Tumor, Ovarian Cancer
NCT ID
NCT02922764
Protocol IDs
RGX-104-001
NCI-2017-00226
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
11.
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
Cancer Type
Brain & Spinal Cord Tumor, Colon/Rectal Cancer, Head and Neck Cancer, Lung Cancer, Neuroendocrine Tumor, Solid Tumor, Thyroid Cancer, Unknown Primary
NCT ID
NCT03157128
Protocol IDs
LOXO-RET-17001
NCI-2017-00976
2017-000800-59
Treatment Sites (1)
Emory University School of Medicine
Atlanta
12.
A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer
Cancer Type
Lung Cancer
NCT ID
NCT02716116
Protocol IDs
AP32788-15-101
NCI-2016-00587
2016-001271-68
U1111-1217-7205
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
13.
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
Cancer Type
Colon/Rectal Cancer, Lung Cancer, Melanoma
NCT ID
NCT02817633
Protocol IDs
4020-01-001
NCI-2016-01254
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
14.
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
Cancer Type
Breast Cancer, Lung Cancer
NCT ID
NCT03845166
Protocol IDs
XL092-001
NCI-2019-03738
15.
A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)
Cancer Type
Lung Cancer, Pancreatic Cancer
NCT ID
NCT02912949
Protocol IDs
MCLA-128-CL01
NCI-2019-06025
2014-003277-42
16.
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
Cancer Type
Lung Cancer, Solid Tumor, Unknown Primary
NCT ID
NCT04931654
Protocol IDs
D9570C00001
NCI-2022-01956
152970
2021-000036-57
17.
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRa)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Cancer Type
Lung Cancer, Solid Tumor
NCT ID
NCT04300556
Protocol IDs
MORAb-202-G000-201
NCI-2020-06147
2019-003600-12
18.
A Study to Test Different Doses of BI 764532 in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3
Cancer Type
Lung Cancer
NCT ID
NCT04429087
Protocol IDs
1438-0001
NCI-2021-01392
2019-000729-31
19.
Accelerated Hypofractionated or Conventionally Fractionated Radiotherapy and Durvalumab in Treating Patients with Stage II-III Non-small Cell Lung Cancer
Cancer Type
Lung Cancer
NCT ID
NCT03801902
Protocol IDs
NRG-LU004
NRG-LU004
NCI-2019-00176
Treatment Sites (4)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
20.
Atezolizumab and Cobimetinib in Treating Patients with Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer
Cancer Type
Lung Cancer
NCT ID
NCT03600701
Protocol IDs
10166
10166
NCI-2017-01812
Treatment Sites (3)
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
21.
NCORP Trial
Biomarker-Driven Therapy and Immunotherapy in Screening Participants with Recurrent or Stage IV Non-Small Cell Lung Cancer (The Expanded Lung-MAP Screening Trial)
Cancer Type
Lung Cancer
NCT ID
NCT03851445
Protocol IDs
LUNGMAP
LUNGMAP
NCI-2018-01540
Treatment Sites (14)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
Renee Gaiter
770-205-5292 x1041
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - Canton
Canton
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Kennestone
Marietta
Greta Dudley
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
22.
NCORP Trial
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer that has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Cancer Type
Lung Cancer
NCT ID
NCT05642572
Protocol IDs
S1900G
S1900G
NCI-2022-09254
Treatment Sites (1)
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
23.
Comparing Photon Therapy to Proton Therapy to Treat Patients with Lung Cancer
Cancer Type
Lung Cancer, Unknown Primary
NCT ID
NCT01993810
Protocol IDs
RTOG-1308
RTOG-1308
NCI-2013-01850
RTOG 1308
Treatment Sites (3)
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
24.
NCORP Trial
Comparing Standard Treatment Alone to Radiation Therapy with or without Surgery with Standard Treatment for Patients with Limited Metastatic Non-Small Cell Lung Cancer
Cancer Type
Lung Cancer
NCT ID
NCT03137771
Protocol IDs
NRG-LU002
NRG-LU002
NCI-2016-00849
Treatment Sites (5)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
25.
Comparison of Surgery to Stereotactic Body Radiation Therapy (SBRT) in Patients With Stage I Non-Small Cell Lung Cancer
Cancer Type
Lung Cancer
NCT ID
NCT05183932
Protocol IDs
202112102-1001
NCI-2022-00200
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
26.
NCORP Trial
Crizotinib in Treating Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Cancer Type
Lung Cancer
NCT ID
NCT02201992
Protocol IDs
E4512
NCI-2014-01507
U10CA180820
U10CA021115
Treatment Sites (22)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
Renee Gaiter
770-205-5292 x1041
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Atrium Health Navicent
Macon
Oncology Research Nurse
4786332152
Cancer Center at DeKalb Medical Center
Decatur
Cathy Comer
404-501-7789
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - Canton
Canton
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Kennestone
Marietta
Greta Dudley
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555
Gwinnett Medical Center
Lawrenceville
404-851-2340
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Piedmont Columbus Regional
Columbus
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
27.
Docetaxel, Ramucirumab, and Pembrolizumab for the Treatment of Metastatic or Recurrent Non-small Cell Lung Cancer in Patients who have Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade Therapy
Cancer Type
Lung Cancer
NCT ID
NCT04340882
Protocol IDs
WINSHIP4950-20
NCI-2020-01134
Treatment Sites (2)
Atlanta VA Medical Center
Decatur
Scott Edelman
404-728-7680
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
28.
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab
Cancer Type
Breast Cancer, Cervical Cancer, Esophogeal Cancer, Head and Neck Cancer, Hodgkin Lymphoma, Lung Cancer, Lymphoma, Stomach/ Gastric Cancer
NCT ID
NCT03674567
Protocol IDs
FLX475-02
NCI-2019-00102
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
29.
Dose-Escalation and Dose-Expansion Study of ZX-4081 in Patients With Advanced Solid Tumors
Cancer Type
Breast Cancer, Colon/Rectal Cancer, Liver Cancer / Hepatoblastoma, Lung Cancer, Melanoma, Ovarian Cancer, Unknown Primary
NCT ID
NCT05118841
Protocol IDs
ZX-4081
NCI-2022-02249
30.
NCORP Trial
Durvalumab vs Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
Cancer Type
Lung Cancer
NCT ID
NCT03833154
Protocol IDs
D9103C00001
NCI-2019-02609
2018-002572-41
Treatment Sites (17)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
Renee Gaiter
770-205-5292 x1041
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Atlanta Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - Canton
Canton
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Kennestone
Marietta
Greta Dudley
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555
Georgia Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Northside Hospital Cancer Institute - Forsyth
Cumming
404-303-3355
University Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
31.
Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer
Cancer Type
Lung Cancer
NCT ID
NCT02200757
Protocol IDs
ALDOXORUBICIN-P2-SCLC-01
Treatment Sites (9)
Northwest Georgia Oncology Centers - Austell
Austell
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Bremen
Bremen
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Carrollton
Carrollton
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Cartersville
Cartersville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Douglasville
Douglasville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Jasper
Jasper
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Marietta
Marietta
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Paulding
Hiram
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Villa Rica
Villa Rica
Mary Gilley
770-281-5131
32.
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
Cancer Type
Bone Tumor, Breast Cancer, Lung Cancer, Prostate Cancer
NCT ID
NCT00882609
Protocol IDs
AMI-2008-01
Treatment Sites (1)
Southcoast Health
Savannah
33.
First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)
Cancer Type
Lung Cancer
NCT ID
NCT05099172
Protocol IDs
21607
NCI-2021-12361
2021-003022-77
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
34.
First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)
Cancer Type
Breast Cancer, Cervical Cancer, Colon/Rectal Cancer, Esophogeal Cancer, Lung Cancer, Ovarian Cancer, Stomach/ Gastric Cancer
NCT ID
NCT03401385
Protocol IDs
DS1062-A-J101
NCI-2018-01200
173812
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
35.
First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b
Cancer Type
Gynecologic Cancers, Lung Cancer, Ovarian Cancer, Primary Peritoneal Cancer, Solid Tumor
NCT ID
NCT03319628
Protocol IDs
XMT-1536-1
NCI-2018-00402
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
36.
GEN1046 Safety Trial in Patients With Malignant Solid Tumors
Cancer Type
Cervical Cancer, Lung Cancer
NCT ID
NCT03917381
Protocol IDs
GCT1046-01
NCI-2020-03735
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
37.
NCORP Trial NCI Priority
Genetic Testing in Screening Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Cancer Type
Lung Cancer, Unknown Primary
NCT ID
NCT02194738
Protocol IDs
NCI-2014-01509
A151216
U10CA180821
U10CA031946
Treatment Sites (28)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
Renee Gaiter
770-205-5292 x1041
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Atlanta VA Medical Center
Decatur
Scott Edelman
404-728-7680
Atrium Health Navicent
Macon
Oncology Research Nurse
4786332152
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
Cancer Center at DeKalb Medical Center
Decatur
Cathy Comer
404-501-7789
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - Canton
Canton
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Kennestone
Marietta
Greta Dudley
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555
Gwinnett Medical Center
Lawrenceville
404-851-2340
Harbin Clinic Cancer Center
Rome
Dilawar Khan, MD
706-528-9110
Low Country Cancer Care Associates, PC
Savannah
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Pearlman Cancer Center at South Georgia Medical Center
Valdosta
Jeffrey Hoy
229-259-4628
Phoebe Cancer Center at Phoebe Putney Memorial Hospital
Albany
Dept of Clinical Research
(229) 312-0406
Piedmont Columbus Regional
Columbus
University Cancer and Blood Center, LLC - Athens Medical Oncology
Athens
Jamie Hodgson
706-353-2990 x279
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
38.
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy
Cancer Type
Lung Cancer, Unknown Primary
NCT ID
NCT05338970
Protocol IDs
U31402-A-U301
NCI-2022-04276
2021-005879-40
jRCT 2021220002
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
39.
Intensity-Modulated Proton Therapy in Treating Patients with Limited Stage or Extensive Stage Small Cell Lung Cancer
Cancer Type
Lung Cancer
NCT ID
NCT04342429
Protocol IDs
RAD4649-19
NCI-2019-02577
40.
Ketorolac before Surgery for the Treatment of Stage I-II Non-small Cell Lung Cancer or Stage III Renal Cell Cancer
Cancer Type
Lung Cancer
NCT ID
NCT04495894
Protocol IDs
WINSHIP4977-20
NCI-2020-02709
Treatment Sites (4)
Emory Clinic
Atlanta
Emory University Hospital - Atlanta
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
41.
Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer
Cancer Type
Lung Cancer
NCT ID
NCT05493566
Protocol IDs
WINSHIP5477-21
NCI-2022-00931
STUDY00003612
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
42.
MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer
Cancer Type
Lung Cancer
NCT ID
NCT04762199
Protocol IDs
WINSHIP5153-20
NCI-2020-08392
43.
NCORP Trial
National Cancer Institute “Cancer Moonshot Biobank”
Cancer Type
Leukemia, Lung Cancer, Multiple Myeloma, Plasma cell neoplasm, Prostate Cancer , Solid Tumor
NCT ID
NCT04314401
Protocol IDs
10323
10323
NCI-2020-00750
Treatment Sites (18)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
Renee Gaiter
770-205-5292 x1041
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Atlanta Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - Canton
Canton
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Kennestone
Marietta
Greta Dudley
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555
Georgia Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Northside Hospital Cancer Institute - Forsyth
Cumming
404-303-3355
University Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
44.
Non-Chemotherapy Treatment (Ramucirumab plus Pembrolizumab) or Standard Chemotherapy for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Trial
Cancer Type
Lung Cancer
NCT ID
NCT05633602
Protocol IDs
S2302
S2302
NCI-2022-09319
45.
Osimertinib in Treating Patients with Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Cancer Type
Lung Cancer
NCT ID
NCT03191149
Protocol IDs
EA5162
EA5162
NCI-2017-01017
Treatment Sites (3)
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
46.
NCORP Trial
Osimertinib with or without Bevacizumab as Initial Treatment for Patients with EGFR-Mutant Lung Cancer
Cancer Type
Lung Cancer, Unknown Primary
NCT ID
NCT04181060
Protocol IDs
EA5182
EA5182
NCI-2019-07941
Treatment Sites (1)
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
47.
Palliative Radiotherapy with Lurbinectedin in Patients with Extensive Stage Small Cell Lung Cancer
Cancer Type
Lung Cancer
NCT ID
NCT05244239
Protocol IDs
RAD5466-21
NCI-2021-12410
STUDY00003528
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
48.
PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Cancer Type
Lung Cancer, Prostate Cancer
NCT ID
NCT03460977
Protocol IDs
C2321001
NCI-2018-01985
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
49.
Phase 1a/1b Study of STK-012 Monotherapy and in Combination With Pembrolizumab in Patients With Solid Tumors
Cancer Type
Brain & Spinal Cord Tumor, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Melanoma, Ovarian Cancer, Solid Tumor, Unknown Primary
NCT ID
NCT05098132
Protocol IDs
STK-012-101
NCI-2022-00633
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
50.
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)
Cancer Type
Lung Cancer
NCT ID
NCT03739710
Protocol IDs
205801
NCI-2018-03390
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
51.
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
Cancer Type
Breast Cancer, Colon/Rectal Cancer, Head and Neck Cancer, Liver Cancer / Hepatoblastoma, Lung Cancer, Melanoma, Ovarian Cancer, Pancreatic Cancer, Sarcoma, Stomach/ Gastric Cancer
NCT ID
NCT04140526
Protocol IDs
ONC-392-001
R44CA250824-01
NCI-2020-06149
20193108
4R44CA250824-02
52.
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies
Cancer Type
Lung Cancer, Lymphoma, Melanoma
NCT ID
NCT04137900
Protocol IDs
TAB004-01
NCI-2020-00511
53.
SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)
Cancer Type
Lung Cancer, Melanoma
NCT ID
NCT04291079
Protocol IDs
SRK-181-001
NCI-2020-05381
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
54.
Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)
Cancer Type
Lung Cancer
NCT ID
NCT03319940
Protocol IDs
20160323
NCI-2017-02043
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
55.
Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer
Cancer Type
Lung Cancer, Unknown Primary
NCT ID
NCT03847519
Protocol IDs
ADXS-503-101
NCI-2019-01784
Treatment Sites (1)
Emory University Hospital - Atlanta
Atlanta
56.
Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer
Cancer Type
Lung Cancer, Melanoma
NCT ID
NCT03809624
Protocol IDs
Ph 1 INBRX-105
NCI-2019-02844
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
57.
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Cancer Type
Lung Cancer, Melanoma, Stomach/ Gastric Cancer
NCT ID
NCT04198766
Protocol IDs
Ph 1 INBRX-106
NCI-2020-06313
MK3475 KEYNOTE A99
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
58.
Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients
Cancer Type
Lung Cancer
NCT ID
NCT04310020
Protocol IDs
S1933
NCI-2020-01543
S1933
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
59.
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors
Cancer Type
Colon/Rectal Cancer, Lung Cancer, Ovarian Cancer
NCT ID
NCT02715284
Protocol IDs
4010-01-001
NCI-2016-01910
60.
Sublobar Resection or Stereotactic Ablative Radiotherapy in Treating Patients with Stage I Non-small Cell Lung Cancer, The STABLE-MATES Trial
Cancer Type
Lung Cancer, Unknown Primary
NCT ID
NCT02468024
Protocol IDs
SCCC-02515; STU 022015-069
NCI-2015-01676
Treatment Sites (1)
Curtis and Elizabeth Anderson Cancer Institute at Memorial University Medical Center
Savannah
Joni N. Shortt, RN, BSN, CCRC
912-350-8913
61.
Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability
Cancer Type
Lung Cancer
NCT ID
NCT04804644
Protocol IDs
NRG-CC009
NRG-CC009
NRG-CC009
NCI-2020-11651
62.
Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)
Cancer Type
Lung Cancer
NCT ID
NCT03811002
Protocol IDs
NRG-LU005
NRG-LU005
NCI-2019-00178
Treatment Sites (5)
Curtis and Elizabeth Anderson Cancer Institute at Memorial University Medical Center
Savannah
Joni N. Shortt, RN, BSN, CCRC
912-350-8913
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Grady Memorial Hospital
Atlanta
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
63.
NCORP Trial
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer (An ALCHEMIST Treatment Trial)
Cancer Type
Lung Cancer
NCT ID
NCT04267848
Protocol IDs
A081801
A081801
NCI-2020-00751
Treatment Sites (18)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
Renee Gaiter
770-205-5292 x1041
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Atlanta Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - Canton
Canton
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Kennestone
Marietta
Greta Dudley
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555
Georgia Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Northside Hospital Cancer Institute - Forsyth
Cumming
404-303-3355
University Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
64.
NCORP Trial
Testing the Addition of an Antibody to Standard Chemoradiation followed by the Antibody for One Year to Standard Chemoradiation followed by One Year of the Antibody in Patients with Unresectable Stage III Non-Small Cell Lung Cancer
Cancer Type
Lung Cancer
NCT ID
NCT04092283
Protocol IDs
EA5181
EA5181
NCI-2019-06124
Treatment Sites (1)
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
65.
NCORP Trial
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
Cancer Type
Lung Cancer
NCT ID
NCT04402788
Protocol IDs
NRG-LU007
NRG-LU007
NCI-2020-03472
Treatment Sites (4)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Georgia Cancer Center for Excellence at Grady
Atlanta
Scott Edelman
404-489-9000
Saint Joseph's Hospital of Atlanta
Atlanta
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
66.
NCORP Trial
Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy with or without Chemotherapy) for Stage IV Non-Small Cell Lung Cancer Patients who are PD-L1 Negative
Cancer Type
Lung Cancer
NCT ID
NCT04929041
Protocol IDs
A082002
A082002
NCI-2021-06042
Treatment Sites (1)
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
67.
NCORP Trial
Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients with Early Non-small Cell Lung Cancer
Cancer Type
Lung Cancer
NCT ID
NCT04214262
Protocol IDs
S1914
S1914
NCI-2019-08627
Treatment Sites (1)
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
68.
NCORP Trial
Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer
Cancer Type
Lung Cancer, Unknown Primary
NCT ID
NCT04310007
Protocol IDs
EA5191
NCI-2020-01541
EA5191
Treatment Sites (2)
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
Summit Cancer Care at the Nancy N. Lewis and J.C. Lewis Cancer & Research Pavilion
Savannah
69.
NCORP Trial
Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer
Cancer Type
Lung Cancer
NCT ID
NCT03793179
Protocol IDs
EA5163
EA5163
NCI-2018-03695
Treatment Sites (14)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
Renee Gaiter
770-205-5292 x1041
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - Canton
Canton
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Kennestone
Marietta
Greta Dudley
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
70.
NCORP Trial
Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
Cancer Type
Lung Cancer
NCT ID
NCT04625647
Protocol IDs
S1900E
S1900E
NCI-2020-08103
Treatment Sites (1)
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
71.
NCORP Trial
Testing Whether the Use of Brain Scans Alone Instead of Brain Scans plus Preventive Brain Radiation Affects Lifespan in Patients with Small Cell Lung Cancer
Cancer Type
Lung Cancer
NCT ID
NCT04155034
Protocol IDs
S1827
NCI-2019-05338
S1827
Treatment Sites (2)
John B Amos Cancer Center
Columbus
Courtney Dean Alexander
706-780-6201
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
72.
VIC-1911 Monotherapy in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer
Cancer Type
Lung Cancer
NCT ID
NCT05374538
Protocol IDs
VIC-1911-01
NCI-2022-05882
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
About Us Research Resources & Education Screening & Genetics Clinical Trials & Providers Cancer Navigators Survivorship Media, News & Events Contact Us Donate Take Our Survey Link to Us

Research

Screening & Genetics

Clinical Trials & Providers

Survivorship

About Georgia CORE

Education & Resources

Media, News & Events

Patient Navigation

Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a statewide nonprofit that leverages partnerships and innovation to attract more clinical trials, increase research, and promote education and early detection to improve cancer care for Georgians in rural, urban, and suburban communities across the state.